Gynecological diseases
Conditions
Interventions
Group S:Intravenous infusion of 0.10 µg/kg of Sufentanil
Group A:Intravenous infusion of 0.75mg of Taijilidine
Group B:Intravenous infusion of 1.00mg of Taijilidine
Sponsors
Foshan Maternity & Child Healthcare Hospital,
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Patients scheduled for hysteroscopic surgery at Foshan Women and Children's Hospital; 2.American Society of Anesthesiologists (ASA) classification grades ? to ?; 3.Aged 18–60 years; 4.Mallampati class I or II; 5.Body mass index between 18 and 30 kg/m²; 6.Sign the informed consent form for the clinical trial;
Exclusion criteria
Exclusion criteria: 1.Allergy or contraindication to any drug used in this study; 2.Use of sedatives (midazolam, barbiturates), psychotropic drugs, or opioids within 7 days prior to surgery; 3.Presence of congenital uterine malformations; 4.Presence of severe cardiac, pulmonary, hepatic, or renal insufficiency; 5.Presence of psychiatric disorders that may interfere with cooperation in evaluation and follow-up; 6.Any condition deemed unsuitable for enrollment by the investigators;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response to hysteroscopic examination; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total propofol dose;NRS score;Recovery time;Perioperative adverse events; | — |
Countries
China
Contacts
Public ContactYifei Chen
Foshan Maternity & Child Healthcare Hospital,
Outcome results
None listed